Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6

Precise and efficient manipulation of genes is crucial for understanding the molecular mechanisms that govern human hematopoiesis and for developing novel therapies for diseases of the blood and immune system. Current methods do not enable precise engineering of complex genotypes that can be easily tracked in a mixed population of cells. We describe a method to multiplex homologous recombination (HR) in human hematopoietic stem and progenitor cells and primary human T cells by combining rAAV6 donor delivery and the CRISPR/Cas9 system delivered as ribonucleoproteins (RNPs). In addition, the use of reporter genes allows FACS-purification and tracking of cells that have had multiple alleles or loci modified by HR. We believe this method will enable broad applications not only to the study of human hematopoietic gene function and networks, but also to perform sophisticated synthetic biology to develop innovative engineered stem cell-based therapeutics.

[1]  A. Reinisch,et al.  A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells , 2016, Nature Medicine.

[2]  W. Woods,et al.  Multiplexed Targeted Genome Engineering Using a Universal Nuclease-Assisted Vector Integration System. , 2016, ACS synthetic biology.

[3]  D. Russell,et al.  AAV-mediated gene targeting methods for human cells , 2011, Nature Protocols.

[4]  L. Zon,et al.  Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. , 2013, Blood.

[5]  Aviv Regev,et al.  Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing , 2014, Nature Biotechnology.

[6]  Jun Seita,et al.  Hematopoietic stem cell: self‐renewal versus differentiation , 2010, Wiley interdisciplinary reviews. Systems biology and medicine.

[7]  Shondra M. Pruett-Miller,et al.  Nuclease-mediated gene editing by homologous recombination of the human globin locus , 2013, Nucleic acids research.

[8]  A. Baiker,et al.  Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. , 2012, Human gene therapy methods.

[9]  R. Bak,et al.  CRISPR-Mediated Integration of Large Gene Cassettes Using AAV Donor Vectors. , 2017, Cell reports.

[10]  Robert Langer,et al.  CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling , 2014, Cell.

[11]  Luigi Naldini,et al.  Gene therapy returns to centre stage , 2015, Nature.

[12]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[13]  Mithat Gönen,et al.  Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection , 2017, Nature.

[14]  Andrew I Su,et al.  Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics' , 2005, Nature Genetics.

[15]  M. van der Burg,et al.  Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells , 2014, Nature.

[16]  Howard Y. Chang,et al.  Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation. , 2015, Cell stem cell.

[17]  Christopher J. Ott,et al.  Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis , 2015, The Journal of experimental medicine.

[18]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[19]  Nevan J Krogan,et al.  A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells. , 2016, Cell reports.

[20]  Steven Lin,et al.  Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery , 2014, eLife.

[21]  Israel Steinfeld,et al.  Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells , 2015, Nature Biotechnology.

[22]  Mark Munsell,et al.  Cord-blood engraftment with ex vivo mesenchymal-cell coculture. , 2012, The New England journal of medicine.

[23]  David Bryder,et al.  Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. , 2014, Cell stem cell.

[24]  U. Choi,et al.  Targeted Repair of CYBB in X-CGD iPSCs Requires Retention of Intronic Sequences for Expression and Functional Correction. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  H. Ochs,et al.  Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome. , 2016, Blood.

[26]  R. Majeti,et al.  Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia , 2015, Nature Medicine.

[27]  I. Weissman,et al.  Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. , 2007, Cell stem cell.

[28]  P. Gregory,et al.  Homology-driven genome editing in hematopoietic stem and progenitor cells using zinc finger nuclease mRNA and AAV6 donors , 2015, Nature Biotechnology.

[29]  Daesik Kim,et al.  Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins , 2014, Genome research.

[30]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[31]  Jennifer A. Doudna,et al.  Generation of knock-in primary human T cells using Cas9 ribonucleoproteins , 2015, Proceedings of the National Academy of Sciences.

[32]  R. Kotin,et al.  Characterization of a preferred site on human chromosome 19q for integration of adeno‐associated virus DNA by non‐homologous recombination. , 1992, The EMBO journal.

[33]  M. Andreeff,et al.  Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. , 2015, Blood.

[34]  Daniel G. Miller,et al.  Adeno-associated virus vectors integrate at chromosome breakage sites , 2004, Nature Genetics.

[35]  Mark Ende,et al.  Hematopoietic stem-cell transplantation. , 2006, The New England journal of medicine.

[36]  Elisa Laurenti,et al.  Hematopoiesis: a human perspective. , 2012, Cell stem cell.

[37]  Vanessa Taupin,et al.  Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo , 2010, Nature Biotechnology.

[38]  Pachai Natarajan,et al.  CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease , 2017, Science Translational Medicine.

[39]  S. Lowe,et al.  p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. , 2010, Genes & development.

[40]  Takashi Yamamoto,et al.  Targeted genome editing , 2014, Development, growth & differentiation.

[41]  G. Sauvageau,et al.  Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal , 2014, Science.

[42]  Aymeric Duclert,et al.  Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. , 2015, Cancer research.

[43]  P. Gregory,et al.  Efficient genome editing in hematopoietic stem cells with helper-dependent Ad5/35 vectors expressing site-specific endonucleases under microRNA regulation , 2015, Molecular therapy. Methods & clinical development.

[44]  Dana Carroll,et al.  Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells , 2016, Science Translational Medicine.

[45]  I. Verma,et al.  Gene therapy: Therapeutic gene causing lymphoma , 2006, Nature.

[46]  Pedro P. Rocha,et al.  Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms , 2015, The Journal of experimental medicine.

[47]  J. Kinney,et al.  Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.

[48]  Sruthi Mantri,et al.  CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells , 2016, Nature.

[49]  A. Hagenbeek,et al.  Safety of retroviral gene marking with a truncated NGF receptor , 2003, Nature Medicine.

[50]  M. Porteus,et al.  Generation of an HIV resistant T-cell line by targeted "stacking" of restriction factors. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  Joana A. Vidigal,et al.  In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system , 2014, Nature.

[52]  Aaron R Cooper,et al.  CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.